Abstract 5093
Background
PDR (Pulsed Dose Rate) Brachytherapy is one of the treatments of choice for cervical cancer. Main side-effects are vaginal dryness, dyspareunia, pain, stenosis and sexual dysfunction that impacts on the patient’s well-being and on quality of life. To evaluate the efficacy of vaginal moisture to reduce dryness and pain associated with PDR Brachytherapy in cervical cancer patients treated at Catalan Institute of Oncology-Barcelona.
Methods
A quasi-experimental randomized study. From 2016 to 2018 all women were assessed by nurses 4 times: basal at discharge, 1st, 3rd and 6th month post-treatment. Experimental intervention with moisturizing versus standard care. Inclusion criteria; women diagnosed of cervical cancer receiving PDR. Probabilistic sampling of patients assigned 42 to control group CG and 47 to experimental group (EG). Variables: vaginal hydration, pain, age, ethnicity, comfort perceived, socio-demographic, tobacco, sexual relationship and couples. Instruments: LENT/SOMA to assess vaginal toxicity and visual numeric for pain.
Results
Of the 96 eligible, some excluded for relapse, or study failure. N = 89 women. Mean age: 52.78 + 12.8 (range 24-83) years old. Ethnicity; 63.8% white, Latina 3.1%, Arabic and Asiatic 0.8% each and gypsies 1.6%. Education; 3.1% illiteracy, primary 32.2%, secondary 25.2% and university 7.2%. Smokers 29.2%. For variable pain was 15-15-17-15 in CG and 20-17-15-13 in EG for consecutive points. Dyspareunia was present in 0-4-8-7 patients and 3-0-2-2 in EG. Dryness was 1-9-13-12 in CG and 6-1-8-10 in EG. Bleeding was 17-5-5-7 in CG and 16-10-0-6 in EG. Only significance differences on dryness variable. A total of 48.31% women avoid sexual intercourse, 22 (24.71%) in CG and 21 (23.59%). No significance differences.
Conclusions
An early vaginal moisturizing post-brachytherapy decreases the appearance of dyspareunia, allows start sexual relationships and improves the quality of life and sense of well-being. However some patients do not give the necessary importance to sexuality and it is something that they put aside during the treatment. Nursing education for patients at discharge helps to facilitate a healthy sexuality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract